PALLAVI SACHDEV

Company: Eisai

Job title: Executive Director

Seminars:

9:00 P-tau217: Clinical Promise, Regulatory Hurdles & the Path to Surrogate Endpoint Status 9:00 am

Highlighted by the recent approval of the first in vivo blood test for Alzheimer’s Disease, advancements in new technologies to measure p-tau217 are at an all-time-high. Join this session for an inside look on how p-tau217 is setting the gold standard in AD diagnostics, exploring its scientific evolution, clinical impact, and regulatory breakthrough, offering a…Read more

day: Pre-Conference Workshop Day

1:00 Alpha-Synuclein Biomarkers: Overcoming Biological Complexity to Transform Parkinson’s & Synucleinopathy Research 1:00 pm

Exploring the evolving role of alpha-synuclein in Parkinson’s and related disorders, focusing on both its promise and its limitations. Delve into the challenges of using alpha-synuclein for patient stratification and monitoring in clinical trials, review cutting-edge blood-based and seed amplification assay technologies that aim to reduce reliance on imaging, and unpack the complex biology of…Read more

day: Pre-Conference Workshop Day

2:15 Roundtable Discussion: Piecing It All Together: How Multi-Omics Reveals Hidden Patterns to Unlock a Deeper Understanding of Disease 2:15 pm

Exploring how integrative multi-omics approaches are transforming our ability to decode disease complexity, particularly in heterogeneous neurological disorders like Alzheimer’s, Parkinson’s, MS, and ALS. Gain insight into how combining omics layers can improve biomarker discovery, support precision medicine, and drive better patient stratification. The limitations of relying on single-omic data in complex, multi-pathway diseases Overview…Read more

day: Conference Day 2